Compare Shell PLC (SHEL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shell PLC vs Spyre Therapeutics Inc. Common Stock — how do they compare? Shell PLC trades at $103.86 (market cap $290.47B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Shell PLC is far larger — about 38.6× Spyre Therapeutics Inc. Common Stock's market cap, and Shell PLC pays a 3.03% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Shell PLC for 91 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SHEL | SYRE | |
|---|---|---|
Market Cap | $290.47B | $7.52B |
Volume | 4,901,394 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $103.58 | $108.92 |
52-Week Low | $70.31 | $22.18 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $332.17B | $6.52B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $103.58, up 1.96% today, near its consensus price target of $103.24. The stock shows bullish momentum with strong earnings beats in Q1 and Q2 2026, though Q4 2025 missed estimates. Recent news highlights expansion in LNG Canada Phase 2, doubling export capacity. Valuation metrics appear reasonable with a P/E of 11.39 and EV/EBITDA of 4.89. Operating cash flow remains robust at $42.86 billion for 2025, supporting dividend payments and strategic investments.
Outlook is positive with analyst consensus favoring Buy ratings (61.54%) and a high price target of $122.40. Key opportunities include LNG growth and portfolio optimization, while risks involve energy price volatility and execution of large-scale projects. The stock's current technical overbought condition may prompt near-term consolidation.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
